A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
Parkinson's Disease
About this trial
This is an interventional treatment trial for Parkinson's Disease focused on measuring Parkinson's disease, levodopa, dyskinesia
Eligibility Criteria
Inclusion Criteria: Aged 30 to 80 years, inclusive, at time of Parkinson's disease diagnosis Idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting tremor, bradykinesia or rigidity Parkinson's disease impairment warranting treatment with a levodopa formulation according to the investigator's assessment Exclusion Criteria: History, signs or symptoms suggesting the diagnosis of atypical or secondary Parkinsonism due to drugs, metabolic disorders, encephalitis or other neurodegenerative diseases History of stereotaxic brain surgery for PD (e.g., pallidotomy, deep brain stimulation, tissue transplant) Diagnosis of Parkinson's disease for more than 5 years prior to Screening Previous use of levodopa in any formulation, entacapone or tolcapone for more than 30 days or anytime within 4 weeks (28 days) prior to baseline Use of a dopamine agonist within 4 weeks (28 days) prior to baseline
Sites / Locations
- Barrow Neurology Clinics at St. Joseph's Hosptial & Medical Center
- Coastal Neurological Medical Group, Inc
- Neurosearch, Inc.
- University of Florida Health Science Center
- Mayo Clinic
- USF Medical Clinic
- Springfield Neurology Associates, LLC
- Clinical Neuroscience Center
- Melbourne Internal Medicine Associates
- Westmoreland Neurology Associates, Inc.
- Lankenau Hospital
- NeuroHealth
- Coastal Neurology, PA
- Senior Adults Specialty Research
- Baylor College of Medicine, Parkinson's Disease Center
- Neurology Associates
- Blue Ridge Research Center at Roanoke Neurological Center
- Heritage Medical Research Clinic
- Eastern Health Care - Health Sciences Centre, Neurology Department
- Neurology Division, Health Science Center
- Cape Breton Regional Hospital, Neurology Department
- Grand River Hospital
- London Health Sciences Center, University Hospital, Rm. A10-026
- Centre for Movement Disorders
- Parkinson's & Neurodegenerative Disorders Clinic
- Ottawa Hospital, Civic Campus
- Hiren Desai Medicine Professional Corporation
- Neuro Rive Sud
- Montreal General Hospital
- Unite des Troubles du Mouvement Andre-Barbeau, CHUM-Hotel-Dieu
- Centre de Recjerche Clinique du CHUS
- Dr. Felix Veloso Research
- Quebec Memory and Motor Skills Disorders Clinic
- University of Saskatchewan, Royal University Hospital
- Neurologická klinika, Univerzita Palackého
- FN-neurologická klinika
- Neurologicka klinika
- FN-Nemocnice Pardubice
- Rambam Medical Center
- Dep. Of Neurology (Bitan 38, EEG institute)
- Belinson Campus, Jabotinsky st. Movement Disorder Unit
- Sourasky Medical Center
- Clinica Neurologica I - Azienda Ospedaliera-Universitaria Policlinico - Università di Catania
- "Dipartimento di Neuroscienze Oftalmologia e Genetica (DINOG)
- Unità Operativa Complessa Neurologia - Policlinico Universitario "G. Martino"
- Istituto Nazionale Neurologico "Carlo Besta"
- Dipartimento di Neuroscienze-Sezione Neurologia Università degli Studi di Pisa- AO S. Chiara
- Dipartimento di Scienze Neurologiche Università degli Studi di Roma "La Sapienza" Roma I
- Dipartimento di Neuroscienze-Università degli Studi di Torino
- A.O. Istituti Clinici di Perfezionamento-Unita'Operativa Centro Parkinson
- Samodzielny Publiczny Szpital Kliniczny Oddzial Kliniczny Neurologii i Epiletologii
- Centrum Neurologii Klinicznej
- Klinika Neruologii Wieku Podeszlego
- Hospitais da Universidade de Coimbra (Serv. Neurologia)
- Hospital de Santa Maria (Serv. Neurologia)
- Hospital de Santo António (Serv. Neurologia)
- Istanbul CAPA Medical School
- Hacettepe Medical School, Department of Neurology
- Dokuz Eylul Medical School, Department of Neurology
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
1
2